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Introduction
Autoimmune rheumatic disease covers a spectrum of 
conditions, including systemic lupus erythematosus (SLE), 
antiphospholipid syndrome (APS), rheumatoid arthritis 
(RA), other inﬂ  ammatory arthropathies/spondylo  arthro-
pathies, systemic sclerosis (SSc), and systemic vascu-
litides. Historically, pregnancy was not deemed safe in 
women with multisystem rheumatic diseases, either 
because of the risk of that their condition would deteri-
orate or because of their medications. As this review will 
show, this view has changed and current opinion is that 
with good disease control, careful planning, and com-
bined management, delivery of healthy babies is often 
possible. Family size is smaller in women with rheumatic 
diseases because of a combination of factors, including 
disease activity, drug exposure, psychosocial factors, and 
self-exclusion [1,2].
Fertility
Inﬂ  ammatory rheumatological diseases aﬀ  ect women of 
childbearing age, and fertility is an important considera-
tion. Fertility is not usually aﬀ  ected by the rheumatic 
diseases; however, factors that impact on female fertility 
include cytotoxic drugs, amenorrhoea accompanying 
severe ﬂ  ares, and renal insuﬃ   ciency [3].
Th   e main cytotoxic drug that poses a threat to fertility 
is cyclophosphamide. It is known to cause premature 
ovarian failure, and the risk is dependent on the age at 
which it is started, the duration of treatment, and the 
cumulative dose. Boumpas and colleagues [4] showed 
that none of the women who were under the age of 
25 years and who had not more than 7 pulses of intra-
venous cyclophosphamide developed sustained amenor-
rhoea. However, all the women who were over 30 years 
and who received at least 15 intravenous pulses of 
cyclophos  pha  mide developed sustained amenorhoea [4]. 
Th   e risk varies with the regime used, and another study 
of 84 patients with SLE showed that two thirds of cases 
had successful pregnancies [5,6].
Elizur and colleagues [7] suggested that fertility preser-
vation should be oﬀ  ered to all women with severe renal/
extrarenal manifestations of SLE or other systemic 
rheumatic diseases requiring cyclophosphamide at doses 
that might preclude them from having their own 
biological child. Options available include ovulation 
induc  tion therapy, oocyte or embryo cryopreservation, 
or  in vivo maturation of oocytes. Ovulation induction 
therapy may promote ﬂ  ares in patients with lupus and 
precipitate thromboembolism in women with anti-
phospholipid antibodies [8].
Eff  ects of the rheumatological disease and 
pregnancy on the mother
Systemic lupus erythematosus
1. Disease activity
Th   ere is much debate in the literature as to whether lupus 
activity increases during pregnancy. Studies have 
involved varied cohorts of patients and controls, making 
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that occur in pregnancy seem to be responsible for 
inducing lupus activity, and it appears that 40% to 50% of 
patients have a measurable increase in disease activity. 
Th   e risk of a severe ﬂ  are is lower and is estimated at 15% 
to 30%. Flares are typically cutaneous, arthritic, or 
hemato logical.  Th  e risk of ﬂ  are is increased if there is 
evidence of a ﬂ  are within 6 months prior to conception, 
active lupus nephritis, very active lupus in the past, and/
or discontinu  a  tion of medication [9-11]. Th   ere is a risk of 
ﬂ  ares in the postpartum period even if disease has been 
in remission before and during pregnancy. Diagnosis of 
lupus ﬂ  are is important to distinguish from pregnancy-
related physio  logical changes or complications. Th  ese 
features are outlined in Table 1 [12].
2. Pregnancy eff  ects
Women with SLE are at an increased risk of developing 
medical complications during pregnancy, regardless of 
whether their lupus is active or not [13]. Owing to 
hormonal changes, the risk of thrombosis is increased 
two to three times during pregnancy and the ﬁ  rst 6 weeks 
after delivery. Th   ere is a 5% to 10% risk that a pregnant 
woman with SLE will develop a thrombosis during this 
period, even in the absence of APS [14].
Women with SLE are at higher risk of maternal 
complications (disease ﬂ  ares, pregnancy-induced hyper-
tension [PIH], pre-eclampsia, eclampsia, diabetes, or 
thrombosis) and fetal complications (recurrent fetal loss, 
growth restriction, or fetal distress in labor) [13]. As a 
result, they tend to have longer hospital stays and a 
higher rate of cesarean section. Maternal mortality, though 
rare, is increased approximately 20 times compared with 
that of women in general in the US [13,15].
Pre-eclampsia is deﬁ   ned as PIH in association with 
proteinuria (greater than 0.3 g in 24 hours) and edema, 
but virtually any organ may be aﬀ  ected. Th   is is a common 
pregnancy-related complication in SLE. About 25% of 
women with SLE develop pre-eclampsia, and the risk is 
higher for women with pre-existing hypertension, a 
history of lupus nephritis, or anti-phospholipid anti-
bodies [13,15]. Diﬀ   erentiating between active lupus 
nephritis and pre-eclampsia is crucial, and it is important 
to note that the two can coexist. Th   e presence of hyper-
tension with recent-onset proteinuria makes pre-
eclampsia more likely than lupus nephritis, as 
hypertension is very rarely an early sign of active renal 
disease. Red or white cells in the urine in the presence of 
proteinuria are more likely to be due to lupus nephritis 
(after excluding infection, bleeding, or calculi). Urinary 
casts are the best marker for active renal lupus. Blood 
tests that help to distinguish active renal disease from 
pre-eclampsia include an increase in anti-double-
stranded DNA (anti-dsDNA) titres or a 25% decrease in 
complement levels (C3 and C4) (even within the normal 
range) or both [12].
Antiphospholipid syndrome
1. Disease activity
APS is characterized by the presence of anti-phospholipid 
antibodies and either vascular thrombosis or pregnancy 
morbidity [16]. Primary APS occurs in isolation in 50% of 
patients, whereas secondary APS can be associated with 
any other autoimmune disease, most commonly SLE. Th  e 
increased risk of thrombosis during all pregnancies is 
increased further in patients with APS and most often 
presents as deep vein thrombosis, pulmonary emboli, 
stroke, hepatic infarction, recurrent miscarriages, and 
premature delivery for fetal distress or pre-eclampsia. 
Anti-phospholipid antibodies may also initiate an 
inﬂ  ammatory process involving the activation of comple-
ment that aﬀ  ects placental function and results in poor 
pregnancy outcomes [17]. Patients with lupus anticoagu-
lant and/or previous pulmonary emboli are at risk of 
pulmonary hypertension that may deteriorate in preg-
nancy which is associated with a 50% risk of maternal 
mortality [18,19].
2. Pregnancy eff  ects
Th   e presence of anti-phospholipid antibodies predisposes 
the patient to PIH, pre-eclampsia, and eclampsia, the last 
of which usually presents as one or more convulsions 
superimposed on pre-eclampsia. Pre-eclampsia may 
occur in patients with APS pregnancy earlier than in 
healthy women, from 22 weeks [20]. HELLP syndrome is 
a thrombotic micro  angiopathic disorder consisting of 
hemolysis, elevated liver enzymes, and low platelets. It 
presents typically in the third trimester but in patients 
with APS may present with pre-eclampsia earlier than in 
healthy women, even as early at 15 weeks of gestation 
[21-24].
Table 1. Features that help to distinguish systemic lupus 
erythematosus disease activity from pregnancy-induced 
changes 
Unreliable features  Reliable features
Facial/palmar erythema  Palpable lupus rash
Arthralgia Synovitis
Anemia Alopecia  (localized)
Low platelets  Leucopenia (new, not drug-related)
Hypertension  Red cells or casts (or both) in urine
Proteinuria  Rising anti-dsDNA (anti-double-stranded DNA) 
 antibodies
Low C4 with normal C3  25% decrease in C3 and C4 (may be in normal 
 range)
Classical pathway activation  Alternative pathway activation
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arthropathies/spondyloarthropathies
1. Disease activity
In RA, provided that disease activity is stable at the time 
of conception, approximately 75% of patients notice an 
improvement in their condition within the ﬁ  rst trimester 
and approximately a quarter go into remission [25]. Th  e 
risk of ﬂ  ares is increased in the postpartum period, and 
the majority of women have ﬂ   ares within the ﬁ  rst 
3  months after delivery but only about 40% are of 
moderate severity [25,26]. Th  e immunological basis for 
these changes remains uncertain but is thought to involve 
changes in regulatory T cells, monocytes, and galacto  sy-
lation levels of immunoglobulin G [27-31].
Pregnancy generally improves physical functioning in 
patients with RA but not in those with ankylosing 
spondylitis. Emotional and mental health during preg-
nancy are unaﬀ  ected in both conditions [32]. Women 
with spondyloarthropathy generally notice an improve-
ment in their peripheral arthritis and uveitis during 
pregnancy [33]; however, spinal disease tends to remain 
unchanged or worsen. Postpartum ﬂ  ares are common in 
the ﬁ  rst 3 months following delivery and are unrelated to 
disease activity during pregnancy, duration of lactation, 
or time of return of menses [14].
2. Pregnancy eff  ects
Pregnancy outcomes for women with RA and spondy  lo-
arthropathies tend to be favorable; however, these 
women have increased lengths of hospital stay, 
increased rate of premature rupture of membranes, and 
higher cesarean section delivery rates in comparison 
with healthy women [15]. Th   ere is no increased risk of 
pre-eclampsia in RA [34].
Systemic sclerosis
1. Disease eff  ects
Scleroderma, the skin changes of SSc, tends not to 
change in pregnancy. Raynaud phenomenon usually 
improves because of the physiological increase in cardiac 
output. Gastroesophageal reﬂ  ux disease is seen to worsen 
but is a common presentation in all pregnant women. 
Recurrent vomiting can cause Mallory-Weiss tears in the 
esophagus already thinned by disease-related ﬁ  brosis; 
therefore, prompt management is of importance in the 
prevention of life-threatening bleeding [35]. One of the 
most serious complications that occurs in pregnant 
women with SSc is renal crisis due to acute-onset severe 
hypertension. A daily increase in serum creatinine and 
lack of proteinuria in the early stages support a diagnosis 
of renal crisis due to SSc. Renal crisis is most common in 
patients with early diﬀ  use SSc (within 5 years of symptom 
onset), anti-tropoisomerase and anti-RNA polymerase III 
antibodies, and exposure to high-dose corticosteroids 
[35]. Pulmonary hypertension is another serious compli-
cation and is associated with 50% maternal mortality, and 
most vigilance is required 48 to 72 hours after delivery. 
Screening should be done before pregnancy, and termi-
nation should be oﬀ  ered if the complication is diagnosed 
in pregnancy [36].
2. Pregnancy eff  ects
Women with SSc have a higher rate of hypertensive 
disease, including pre-eclampsia, and have an increased 
length of hospital stay compared with normal women 
[15]. Elevated liver function tests and proteinuria with 
edema are more common in pre-eclampsia and HELLP 
syndrome than in SSc renal crisis. Hypertension or renal 
dysfunction due to pre-eclampsia, but not due to active 
SSc, will be resolved by delivery [12].
Vasculitides
1. Disease eff  ects
Th   ere are very few prospective studies of vasculitides in 
pregnancy. Vasculitides can occur at any age but are 
generally more frequent in men and in women beyond 
their reproductive period [37]. Planning conception at a 
time of disease inactivity usually allows women with 
Wegener granulomatosis (WG), polyarteritis nodosa 
(PAN), or Churg-Strauss syndrome to remain well during 
pregnancy. Th   ey are at risk of deteri  or  ation during preg-
nancy and the ﬁ  rst 6 weeks after delivery should concep-
tion occur when the disease is inadequately treated or 
newly active [38,39].
Only 38 cases of WG have been reported in the 
literature: 21 were in remission at conception, 13 were 
diagnosed during pregnancy, and 4 had active disease at 
the time of conception. Flares have a bimodal distri  bu-
tion, most commonly occurring either in the ﬁ  rst  or 
second trimester or in the month after delivery. Maternal 
death has been reported twice, once following thera  peutic 
abortion and once 1 month after delivery [38,  40,  41].
Th   ere are eight reports of pregnancy and PAN 
[12,39,42]. Conceiving at a time when PAN is active puts 
the mother at higher risk of death; hence, therapeutic 
abortion is recommended in the early phase of preg-
nancy, or high-dose corticosteroids with cyclophos  pha-
mide are recommended in the late stages [39].
In Churg-Strauss syndrome, respiratory and cardiac 
systems are most commonly aﬀ   ected during relapse. 
Asthma is more common but cardiac involvement can 
lead to irreversible myocardial damage requiring heart 
transplantation, so careful pre-pregnancy screening and 
management of pregnancy are critical [39,43].
In Takayasu arteritis (TA), severe aortic valvular 
disease and aortic aneurysm are risk factors for maternal 
morbidity and fatality; therefore, pregnancy is dis-
couraged in these patients [39]. Less frequently, heart 
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been reported. Despite these complications, the outcome 
of pregnancy is generally favorable provided that there is 
little delay in seeking medical advice [44].
Behçet disease (BD) improves during pregnancy in 
most patients; however, exacerbations occurred in about 
a sixth of patients in a case control study [45]. BD is 
associated with an increased risk of thrombosis and 
vascular involvement, including central venous throm-
bosis [46].
2. Pregnancy eff  ects
Hypertensive disease is more common in women with 
WG and renal involvement than in normal pregnant 
women. It is the presenting feature in TA and pregnancy, 
and pre-eclampsia complicated 62% of cases in a recent 
single-center Indian study [47]. Pregnancy complications 
and cesarean section were signiﬁ   cantly higher in BD 
patients than in controls [45], as with most other 
vasculitides, particularly TA and WG. Like lupus 
nephritis, renal vasculitis needs to be distinguished from 
pre-eclampsia; however, blood tests (c-ANCA [anti-
neutrophil cytoplas  mic antibody and classical cyto  plas-
mic staining complete heart block] and anti-PR3 [anti-
proteinase-3]) are helpful only in diagnosing renal 
vasculitis due to WG.
Eff  ects of the autoimmune disease on the fetus
Fetal loss
‘Fetal loss’ incorporates spontaneous abortion from less 
than than 10 weeks, miscarriages from 10 to 19 weeks, 
and stillbirths from 20 weeks of gestation. Th  e most 
important factors in predicting fetal loss in SLE, APS, 
SSc, and vasculitis are previous fetal loss, disease activity 
at conception (especially renal), maternal hypertension, 
and the presence of anti-phospholipid antibodies [12,48]. 
Fetal loss is not increased in those with inﬂ  ammatory 
arthropathies or spondylo  arthro  pathies in the absence of 
maternal complications.
Intrauterine growth restriction
Th   e risk of intrauterine growth restriction (IUGR) in SLE 
and APS pregnancies is about three times that in controls 
[15]. Th   e risk of IUGR is increased in those with active 
disease at conception and in those with anti-phospholipid 
antibodies [9,11,16]. IUGR increases the risk of pre  ma-
ture delivery and is thought to occur due to utero-
placental dysfunction secondary to thrombosis and 
comple  ment activation; however, the exact mechanisms 
are unknown [17].
Premature delivery
Premature delivery, which is deﬁ  ned as occurring before 
38 weeks of gestation, is common in lupus, APS, SSc, and 
the vasculitides [12,13,35,44,49]. Pre-term delivery is not 
associated with RA [34]. Th   e most important compli  ca-
tion of premature delivery is respiratory distress syn-
drome. In this condition, the newborn can suﬀ  er from 
respiratory distress due to insuﬃ   cient  surfactant.  If 
premature delivery is imminent, the mother should be 
given a course of corticosteroids to promote fetal lung 
development at least 24 hours before birth. Th  e  current 
UK guidelines recommend two doses of betamethesome 
12 mg intramuscularly (12 hours apart) or four doses of 
dexamethasone 6 mg (12 hours apart) [50].
Neonatal lupus
Neonatal lupus is a model of passive autoimmunity in 
mothers who carry anti-Ro (SSA) or anti-La (SSB) anti-
bodies or both. Antibodies cross the placenta from about 
week 16 and are associated with (a) irreversible con  genital 
complete heart block (CHB) in the fetus or (b) transient 
photosensitive rash on the face or scalp or various liver 
and hematological abnormalities or neuro  logical manifes-
tations in the newborn or (c) both. CHB is deﬁ  ned as 
atrioventicular block diagnosed in utero, at birth, or within 
the neonatal period (0 to 27 days after birth) and is present 
in approximately 1% to 2% of women with anti-Ro/La 
antibodies [51-53]. CHB is permanent, and although most 
children do well with pacemakers, the cumulative 
probability of survival at 3 years of age was only 80% in one 
report [52]. Neonatal lupus rash is present in 10% to 20%, 
and laboratory abnormalities (anemia, thrombocytopenia, 
neutropenia, and abnormal liver function tests) were 
detected in up to 27% of babies in a prospective study [51]. 
Th  e risk of recurrence of CHB is about 20% in a 
subsequent pregnancy after an aﬀ  ected child [53].
Women who are at risk of having a baby with CHB are 
recommended to have regular monitoring [54], but 
guide  lines vary among countries and among units. In the 
UK, the midwife should listen to fetal heart rate on a 
weekly basis to identify bradycardia from week 16 
onwards and the baby should have heart rate conﬁ  rmed 
while being scanned monthly. Formal fetal echocardio-
graphy occurs at the 20-week anomaly scan, and further 
echocardiograms are done if an abnormality is suspected. 
Partial heart block can be identiﬁ   ed on fetal electro-
cardiogram [54]. Intravenous immunoglobulin (IVIG) 
has been reported to successfully treat severe thrombo-
cytopenia associated with neonatal lupus [55], but IVIG 
does not prevent recurrence of CHB [56]. All babies born 
to mothers with anti-Ro/La should have an electro  cardio-
gram after birth to look for ﬁ  rst- and second-degree heart 
block as they may progress to third-degree later.
Neonatal autoimmune thrombocytopenia
Transmission of anti-platelet antibodies across the 
placenta in women with APS is recognized to cause 
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as intracranial hemorrhage [57]. Th  rombocytopenia 
usually resolves within 6 months as the mother’s anti-
bodies are cleared from the circulation. IVIG may be 
used as treatment for severe thrombocytopenia [58].
Pre-pregnancy considerations
To avoid or reduce the complications discussed above, 
pre-pregnancy planning and screening must be carefully 
undertaken. Combined care involving rheumatologists, 
nephrologists, hematologists, or other relevant physi-
cians, obstetricians, and anesthetists is preferred for all 
but simple inﬂ  ammatory arthropathies. Management of 
the pregnant patient with inﬂ  ammatory rheumato  logical 
disease should be tailored to the individual’s disease 
activity and history. Pregnancy during disease remission 
provides the best results as described above, and patients 
should be advised not to get pregnant until the disease 
has been well controlled for 6 months on non-teratogenic 
drugs that can be continued in pregnancy to reduce the 
risk of ﬂ  ares. A review of all medication that might aﬀ  ect 
pregnancy should be undertaken.
Side eﬀ  ects of teratogenic medication, such as metho-
trexate, cyclophosphamide, mycophenolate mofetil, or 
leﬂ   unomide, must be discussed prior to commencing 
treatment, and information on contraceptive methods 
should be oﬀ   ered with advice on when the drugs and 
contraception should be stopped prior to pregnancy 
(Table  2). Most contraceptive choices, including emer-
gency contraceptive choices, can be oﬀ  ered to patients 
with rheumatological diseases, but there is a potential risk 
of thrombosis in APS if the patient is not fully anti-
coagulated. Estrogen-containing contraceptives can be 
used with care in patients with mild non-active lupus but, 
owing to the increased risk of thrombosis, should be 
avoided in women with anti-phospholipid antibodies or 
APS [59-61].
Disease activity should be assessed by standard criteria 
for each disease and potential risk factors for pregnancy 
complications – including anti-Ro/-La and anti-phosp-
ho  lipid antibodies (including IgG and IgM anti-
cardiolipin and β2 glycoprotein-I antibodies and lupus 
anticoagulant), hypertension, and diabetes and raised 
serum creatinine, 24-hour proteinuria, or protein/
creatinine ratio – should be identiﬁ   ed [12,48]. Echo-
cardio  graphy and lung function tests should be done if 
there have been cardiac, lung, or thrombotic complic-
ations, particularly if there is a risk of pulmonary hyper-
tension [18,19,36].
As with other women planning pregnancy, a healthy 
diet and appropriate exercise are recommended and 
smoking, using illicit drugs, or drinking alcohol are 
discouraged. Folic acid (0.4 mg) should be started 
3  months prior to pregnancy and continued until 
12 weeks of gestation to prevent neural tube defects [62]. 
Women taking folate antagonists such as sulphasalazine 




A summary of drugs available for use in patients with 
inﬂ  ammatory rheumatological conditions in pregnancy is 
provided in Table 2. Speciﬁ  c attention should be given to 
the most commonly used drugs: analgesia, cortico-
steroids, sulphasalazine, azathioprine, hydroxychloro-
quine, aspirin, and heparin and those that are contra-
indicated [49,63-66].
Paracetamol is the ﬁ   rst-line analgesic. Mild opioids 
such as codeine or pethidine are preferred if needed, as 
they can be easily reversed. Th  e concerns are that the 
newborn may present with respiratory depression or 
opioid dependency or both [67]. Tramadol has embryo-
toxic eﬀ  ects in animals and should be avoided.
Corticosteroids can be divided into non-ﬂ  uorinated 
steroids (prednisolone and methyprednisolone) and 
ﬂ  uorinated steroids (betamethasone and dexamethasone) 
[64]. Approximately 90% of prednisolone is metabolized by 
the enzyme 11-β-hydroxysteroid dehydrogenase in the 
placenta; as a result, about 10% reaches the fetus. It is 
widely used, therefore, to treat maternal disease or ﬂ  ares 
(or both) in pregnancy. Fluorinated steroids are not 
metabolized by the placenta and reach the fetus in their 
active form. Th  ese steroids are used to treat or prevent 
fetal complications, but reversal of CHB has not been 
achieved [54,64,68]. All steroids increase the maternal risk 
of hypertension, pre-eclampsia, premature rupture of 
membranes, infection, and diabetes, so the lowest eﬀ  ective 
dose must be used (ideally not more than 15 mg/day).
Sulphasalazine has been used for many years for arthro-
pathies and inﬂ   ammatory bowel disease in preg  nancy. 
Hydroxychloroquine is an anti-malarial used mainly in the 
treatment of SLE and reduces the risk of maternal disease 
ﬂ   are and possibly thrombosis and does not cause fetal 
damage. Women are recommended to continue with 
hydroxychloroquine throughout preg  nancy and lactation 
[14,69]. Azathioprine is a cytotoxic immunosuppressant 
used mainly in SLE and vasculitis. Th  e fetus lacks the 
enzyme inosinatopyrophophorylase, which is required to 
convert azathioprine to its active metabolite 
6-mercaptopurine, and therefore azathioprine is safe to 
use in pregnancy. Azathioprine can be used to control 
severe maternal disease, and doses of not more than 2 mg/
kg per day are associated with few side eﬀ  ects [64].
Treatment and prevention of fl  ares
Provided that conception occurs during remission, the 
risk of ﬂ  ares is low. Th   e patient’s condition should be kept 
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during pregnancy
Class Drug  Fetal  eff  ects  Recommendation
Analgesic  Paracetamol  Not known to be harmful  Can be used during pregnancy
Analgesic (high dose)   Aspirin  Low dose (antithrombotic dose) 75 mg daily is safe and  Can be continued throughout
and antiplatelet agent     lowers risk of premature delivery and pre-eclampsia.   pregnancy
(low dose)     At higher doses (analgesic doses), there is potential risk of 
    impaired renal function, pulmonary hypertension, or clotting 
    ability in newborn. 
Anti-infl  ammatory   NSAIDs  If given within 14 days of delivery, premature closure of  Discontinue at 32 weeks of gestation, 
(analgesic) drugs     ductus arteriosus, which can lead to pulmonary hypertension.   earlier if premature delivery suspected. 
    Possible risk of cardiac septal defects and gastroschisis  Need 2-week gap between stopping 
      NSAIDs and delivery. If needs to be 
      used, ibuprofen preferred to 
      diclofenac as shorter half-life.
Analgesic  Codeine  Respiratory depression and withdrawal symptoms in   Use at lowest eff  ective dose, but avoid
    neonate if opioid used during delivery  during labor.
Analgesic  Pethidine  Respiratory depression and withdrawal symptoms in   Can be used during pregnancy
    neonate if opioid used during delivery 
Analgesic  Tramadol  Embryotoxicity in animals  Avoid during pregnancy
Analgesic  Morphine  Respiratory depression and withdrawal symptoms in   Avoid during pregnancy
    neonate if opioid used during delivery
Anti-infl  ammatory   Cyclo-oxygenase  Impaired renal function, decreased fetal urine output,   Should be avoided
(analgesic) agent  inhibitors  development of oligohydramnios. Teratogenic in animal 
 (COX  inhibitors)  studies.
Immunosuppressive   Corticosteroids  Prolonged treatment >15 mg/day increases risk of premature  Can be continued in pregnancy but
agents    rupture of membranes and preterm labor. Increased risk of   should be lowest eff  ective dose. (See
    oral cleft and palate at high doses.  ‘Drugs’ subsection of ‘Management of 
     pregnancy’  section.)
Disease-modifying  Hydroxycholoquine  No associated congenital abnormalities or malformations  Can be continued throughout 
agent     pregnancy
Disease-modifying   Sulphasalazine  Folic acid antagonist. Associated with two- to threefold  Can be continued in pregnancy but
agent    increased risk of oral clefts and cardiovascular anomalies.   requires folic acid supplementation
    Risk diminished by concomitant use of folic acid throughout   throughout pregnancy
   pregnancy. 
Disease-modifying  Azathioprine  Small risk of depressed hematopoiesis in infant in doses of   Can be continued in pregnancy, not
agent    >2 mg/kg per day  more than 2 mg/kg per day
Disease-modifying  Ciclosporin  No increase in rate of birth defects but risk of maternal   Can be continued in pregnancy up to
agent    hypertension and intrauterine growth restriction  dose of 2.5 mg/kg per day
Disease-modifying  Cyclophosphamide  Embryopathy with growth defects, developmental delay,   Discontinue at least 3 months prior to
agent    craniofacial defects, or distal limb defects  conception. Eff  ective contraception 
      vital during this time.
Disease-modifying  Methotrexate  Increased risk of congenital abnormalities in central nervous   Discontinue 3 months prior to
agent    system, cranial ossifi  cation, limbs, palate, and growth   conception. Wait at least one
    retardation.  menstrual cycle after stopping drug 
      before trying to conceive.
Disease-modifying Lefl   unomide  Inhibits  de novo synthesis of pyramidine in activated   Stop 2 years before conception or use
agent    lymphocytes, leads to increased risk of embryotoxicity and   washout procedure with
    teratogenicity in animals.  cholestyramine.
Disease-modifying  Mycophenolate  Recently identifi  ed phenotype of craniofacial malformations   Discontinue and switch to
agent mofetil  aff  ecting oral cavity and ears as well as ocular anomalies.   azathioprine at least 3 months prior to
    Less frequently, limb abnormalities, with congenital   conception.
    cardiovascular, renal, or central nervous system malformations. 
Disease-modifying  Gold salts  Cross placenta, found in fetal liver and kidneys, no evidence   May be continued
agent    of increase in neonatal malformations in small number of 
   reports  available 
Biological agent  Tumor necrosis factor-  No toxic eff  ects in animals, sporadic adverse events in humans   Discontinue at missed period or
  alpha inhibitors (for   but insuffi   cient to determine toxicity or safety  positive pregnancy test.
 example,  infl   iximab, 
 etanercept,  adalimumab)
Continued overleaf
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pregnancy, such as prednisolone, hydroxychloroquine, 
sulphasalazine, and azathioprine. If these drugs are 
stopped, there is an increased risk of ﬂ  are [14,69,70].
Mild ﬂ  ares of lupus, vasculitis, or arthritis are usually 
treated with low-dose prednisolone (less than 15 mg per 
day). Higher doses or intravenous pulse methylpredniso-
lone is used for severe ﬂ  ares. Non-teratogenic medication 
such as azathioprine, ciclosporin, or tacrolimus may be 
used. Cyclophosphamide and mycophenolate mofetil are 
occasionally used when all other options have been 
exhausted in the third trimester [11,38,39].
Management of recurrent pregnancy losses
Managing recurrent fetal losses depends on under  stand-
ing the mechanism(s) underlying fetal loss. Th  ree  speciﬁ  c 
causes have been identiﬁ   ed: disease activity (which is 
controlled as discussed above), maternal com  pli  cations 
such as pre-eclampsia, or thrombosis. Th  rombosis is 
most commonly associated with anti-phospholipid 
antibodies, and treatment occurs in one of two ways. Th  e 
ﬁ   rst is the use of antiplatelet/anticoagulant therapy, 
mainly aspirin and heparin. In the literature, there is 
much debate about the correct regime, and optimal doses 
have not been agreed upon. Th  e current recommended 
guideline for women who have recurrent miscarriages is 
combination therapy of low-dose aspirin with low-
molecular-weight heparin [64,71,72]. A randomized, 
controlled trial found no diﬀ   erence between giving 
aspirin only versus giving aspirin and heparin [73]. 
However, in that trial (as in a number of studies), not all 
patients had conﬁ   rmed APS according to the Sydney 
criteria, making results diﬃ   cult to interpret [16].
Treatment and prevention of hypertension{
Non-teratogenic anti-hypertensives should be taken 
before and during pregnancy. Labetalol, nifedipine, 
methyl  dopa, and hydralazine are used to control hyper-
tension. Angiotensin-converting enzyme inhibitors and 
angiotensin receptor blockers are contraindicated because 
Table 2. Continued
Class Drug  Fetal  eff  ects  Recommendation
Biological agent  Abatacept  Crosses placenta in animals, no data in human pregnancies  Discontinue at least 10 weeks prior to 
     conception.
Biological agent  Anakinra  No evidence with human pregnancy  Discontinue use prior to conception.
Biological agent  Rituximab  Actively transported across placenta, with neonatal levels   Discontinue 1 year prior to
    being higher than maternal levels. Can lead to transient B-cell   conception.
    depletion in neonate, no infections reported. 
Prevention or   Bisphosphonates  Cross placenta and accumulate in fetal bone, causing bone  Discontinue 2 years before planned
treatment of     abnormalities in animals.  pregnancy as retained in human
osteoporosis      skeleton and released in circulation for 
      at least 2 years after stopping drug.
Prevention or   Calcium and  Therapeutic doses unlikely to be harmful  Can be continued in pregnancy
treatment of   vitamin D
osteomalacia and   supplements
osteoporosis
H2 blocker to   Ranitidine  Not known to be harmful  Can be continued in pregnancy
reduce gastric       (extensive experience)
acid production  
Proton pump   Omeprazole  Not known to be harmful  May be continued (less experience)
inhibitors (lansoprazole) 
Anti-hypertensive   Angiotensin-  Adversely aff  ect fetal and neonatal blood pressure control  Discontinue 3 months prior to
agent  converting enzyme  and renal function. Skull defects and oligohydramnios have   conception. Contraindicated in
  inhibitors  been reported.  pregnancy except possibly in 
      scleroderma renal crisis.
Anti-hypertensive   Calcium channel  No signifi  cant abnormalities  Can be continued in pregnancy (more
agent and vasodilator  blockers    experience with nifedipine than 
      amlodipine or others)
Anticoagulant  Heparin  Does not cross placenta and is not associated with   Can be continued in pregnancy, but
    congenital defects.  owing to heparin-induced osteopenia, 
      calcium and vitamin D supplements 
     are  needed
Anticoagulant  Warfarin  Risk of fetal warfarin syndrome  Contraindicated in fi  rst and third 
      trimesters of pregnancy but can be 
      used in postpartum period
NSAID, non-steroidal anti-infl  ammatory drug.
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Page 7 of 12of teratogenicity. Th  ey are the mainstay of treatment in 
renal crisis of SSc and may be used after appropriate 
discussion with the mother if hypertension is life-
threatening [36]. Aspirin may reduce pre-eclampsia and 
prematurity. Many centers use it in high-risk pregnancies, 
including lupus and other systemic autoimmune diseases, 
to reduce the risk of pre-eclampsia and thrombosis 
[74,75]. If pre-eclampsia is severe or progresses to 
eclampsia, delivery is the deﬁ  nitive treatment.
Treatment of esophageal refl  ux and dyspepsia
Dyspepsia is a common symptom in pregnant women 
and can be worsened by aspirin, non-steroidal anti-
inﬂ  ammatory drugs, and corticosteroids. Antacids such 
as gaviscon are rarely suﬃ   cient. Ranitidine, a histamine-
2-antagonist, is used at doses of between 150 and 600 mg 
daily, especially in patients with SSc [76,77]. Th   ere is less 
experience with proton pump inhibitors such as 
omeprazople, but they are probably safe in pregnancy 
[76,78].
Delivery
Women with chronic disease generally want to have a 
‘natural’ delivery like healthy women. With eﬀ  ective pre-
pregnancy planning and joint care, vaginal delivery 
should be possible; cesarean delivery is reserved for 
obstetric emergencies, those with a history of cesarean 
section who do not want a trial of vaginal delivery, and 
women with severe hip disease. However, to reduce the 
risk of stillbirth in patients with APS or active disease, 
induction may be advisable at 38 to 39 weeks. Detailed 
plans for delivery should be made by a multi-disciplinary 
team that includes the obstetrician, anesthetist, and 
relevant physicians at 36 weeks of gestation or earlier in 
patients with complications. Owing to the risk of placental 
insuﬃ   ciency in SLE, APS, SSc, and vasculitis, babies need 
to be monitored by growth scans every 4 weeks throughout 
pregnancy and closely monitored during delivery for any 
signs of fetal distress. Disease-speciﬁ  c considerations for 
anesthesia are listed in Table 3.
Epidural can be oﬀ  ered for routine vaginal deliveries. 
For cesarean section, neuroaxial anesthetic can be 
performed; general anesthetic is reserved for obstetric 
emergencies (for example, placental abruption, uterine 
rupture, prolapsed umbilical cord, or fetal distress). Th  e 
last dose of heparin should be given 12 hours before the 
epidural will be administered, and the ﬁ   rst dose after 
delivery should be 12 hours later. Aspirin may be given 
up until the time of delivery and is compatible with spinal 
and epidural anesthesia, although practice still varies 
among centers [79].
Breastfeeding
Breastfeeding has multiple health beneﬁ  ts for both the 
mother and child (Table 4) [80]. Table 5 summarizes 
Table 3. Disease-specifi  c complications that may aff  ect use of analgesia and anesthesia 
Disease  Complications that may aff  ect use of analgesia and anesthesia
Systemic lupus erythematosus  Pericarditis or valvular abnormalities
  Pulmonary hypertension, pleural eff  usions, or lupus pneumonitis
  Peripheral neuropathies, central nervous system dysfunction (seizures), or psychological problems
  Hematological abnormalities (anemia, thrombocytopenia, or coagulopathy)
 Lupus  nephritis
Antiphospholipid syndrome  Coexisting autoimmune disease, secondary organ involvement, and thrombotic phenomena, including pulmonary 
 hypertension
 Anticoagulation 
Rheumatoid arthritis  Cervical spine involvement (exclude atlantoaxial anterior subluxation and avoid excessive manipulation of neck during 
 general  anesthesia)
  Hip disease that might prevent vaginal delivery
 Pleural/pericardial  eff  usions and pulmonary parenchymal involvement
Ankylosing spondylitis  Assess presence of extra-articular (cardiopulmonary) features and use of opiate analgesics
  Temporo-mandibular joint dysfunction, cervical and lumbar spine (for general, epidural, or spinal anesthesia), and hip 
  involvement (for vaginal delivery) 
Systemic sclerosis  Renal disease, systemic hypertension, pulmonary hypertension, or cardiac dysfunction
  Assess peripheral pulses, peripheral venous access, extent of Raynaud phenomenon, and skin involvement
Vasculitis  Organ ischemia (cardiac, renal, cerebral, and limb) and intravascular volume
  Monitor hypertension and end organ complications or thrombosis
Table 4. Benefi  ts of breastfeeding
Reduced risk in child   Reduced risk in mother 
Infections  Type 2 diabetes
Atopic dermatitis  Breast cancer
Asthma (young children)  Ovarian cancer
Obesity  Postpartum depression (if not stopped early)
Type 1 and 2 diabetes 
Childhood leukemia 
Sudden infant death syndrome 
Necrotising enterocolitis 
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[49,63-66]. It is widely agreed that prednisolone, sulpha-
sala  zine, and hydroxychloroquine are acceptable [64,  69, 
81]. Azathioprine use during lactation remains more 
controversial [64,81] but has been used by us and others 
without obvious harm to the infant, as levels of the active 
metabolites are rare in breast milk and undetectable in 
the baby [64,82,83].
Conclusions
With careful planning, most women with inﬂ  ammatory 
rheumatological diseases can have successful pregnan  cies 
(Table 6). It is important that conception occur when the 
disease has been inactive for at least 6 months and while 
the mother is taking non-teratogenic drugs. Th  e  mother 
and fetus require regular monitoring throughout 
pregnancy so that any complications can be detected 
Table 5. Commonly used anti-rheumatic drugs and their use during breastfeeding
Drug  Crosses into breast milk  Compatible with lactation
Paracetamol  Amount too small to be harmful  Can be continued during breastfeeding
Aspirin  Possible risk of Reye syndrome  Low doses (antithrombotic dose of 75 mg/day) acceptable, 
  In large doses, could impair platelet function  but avoid in large doses
NSAIDs  Very small quantities in human breast milk  Approved for use (use short-acting NSAIDs such as
   Potential risk of jaundice and kernicterus  ibuprofen)
Codeine  Amount usually too small to be harmful; however,   Use lowest eff  ective dose if needed, but try to avoid
  mothers vary in capacity to catabolize codeine and infant 
  at risk of morphine overdose 
Pethidine  Present in breast milk but not known to be harmful  Can be used
Tramadol  Amount probably too small to be harmful  Should be avoided
Morphine  Therapeutic doses unlikely to aff  ect infant  Therapeutic doses may be used if needed, but try to avoid
  Withdrawal symptoms in infants of dependent mothers
Corticosteroids  Trace amounts of hydrocortisone and up to 25% of   Breastfeed 4 hours after last dose to minimize exposure if
  maternal levels of prednisolone detectable in breast milk  prednisolone of greater than 20 mg
COX-2 (cyclo-oxygenase-2)   Insuffi   cient data in humans  Avoid due to theoretical risk
inhibitors
Hydroxychloroquine  Found in breast milk but no abnormalities reported  Can be continued during breastfeeding
Methotrexate  Excreted in low concentrations into breast milk  Contraindicated 
Lefl  unomide  No published data available  Contraindicated due to theoretical risk
Sulfasalazine  Negligible amounts secreted in breast milk  To be used with folic acid supplements
Gold salts  Excreted in breast milk and absorbed by infant  Should be avoided
  Can lead to rash, nephritis, hepatitis, and hematological 
 problems
Azathioprine  Azathioprine and its metabolites detected in breast milk   May be used at not more than 2 mg/kg per day after
  in low amounts, but abnormalities rare  discussion with mother weighing up risk-benefi  t
Cyclosporin  Wide variability in drug disposition  May be used after discussion with mother weighing up 
    risk-benefi  t, preferably at doses lower than 2.5 mg/kg per day
Cyclophosphamide  Excreted in breast milk  Contraindicated
Mycophenolate mofetil  No human studies  Contraindicated due to theoretical risk
Tumor necrosis factor-alpha   Etanercept excreted in breast milk  Not enough data, therefore should be avoided
antagonists (for example,   Infl  iximab undetectable
infl  iximab, etanercept, and   No studies with adalimumab
adalimumab)
Anakinra  Unknown whether excreted in breast milk  Not enough data, therefore should be avoided
Abatacept  Not known whether excreted in breast milk or whether   Contraindicated due to theoretical risk
  absorbed systematically after ingestion 
Rituximab  Unknown whether excreted in breast milk  Not enough data, therefore should be avoided
Intravenous immunoglobulin   No published data  May be used during breastfeeding after discussion 
weighing up risk-benefi  t
Heparin and low-molecular-  Not excreted in breast milk  Can be continued during breastfeeding
weight heparin
Warfarin  Minimal excretion in breast milk  Can be used while breastfeeding
NSAID, non-steroidal anti-infl  ammatory drug.
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Page 9 of 12early and managed appropriately. Combined care involv-
ing obstetricians, rheumatologists, other relevant physi-
cians, and anesthetists will promote the best outcomes 
for mother and baby.
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